Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Adlai Nortye (NASDAQ: ANL) will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, held October 22–26, 2025.
Presentation: “Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload.”
Date & Time: Saturday, October 25, 2025, 11:45 AM–12:15 PM ET, Level 3 Ballroom AB, Hynes Convention Center. The company will release scientific rationale and data highlights after the abstract posts on October 22, 2025.
Adlai Nortye (NASDAQ: ANL) terrà una presentazione orale alla AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics a Boston, in programma dal 22 al 26 ottobre 2025.
Presentazione: “Scoperta di AN4035: un nuovo anticorpo che coniuga un farmaco coniugato (ADC) mirato a CEACAM5, dotato di un payload inibitore pan-RAS(ON) proprietario.”
Data e ora: sabato 25 ottobre 2025, dalle 11:45 alle 12:15 ET, Sala Ballroom AB, Livello 3, Hynes Convention Center. L'azienda rilascerà la motivazione scientifica e i punti salienti dei dati dopo la pubblicazione dell'abstract il 22 ottobre 2025.
Adlai Nortye (NASDAQ: ANL) presentará una ponencia oral en la AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics en Boston, que se celebrará del 22 al 26 de octubre de 2025.
Presentación: “Descubrimiento de AN4035: un nuevo conjugado anticuerpo-fármaco (ADC) dirigido a CEACAM5, armado con una carga de inhibidores pan-RAS(ON) propietaria.”
Fecha y hora: sábado, 25 de octubre de 2025, de 11:45 a.m. a 12:15 p.m. ET, Level 3 Ballroom AB, Hynes Convention Center. La empresa divulgará la justificación científica y los puntos destacados de los datos después de la publicación del resumen el 22 de octubre de 2025.
Adlai Nortye (NASDAQ: ANL) 는 2025년 10월 22일부터 26일까지 보스턴에서 열리는 AACR-NCI-EORTC 국제 학술대회인 ‘분자 표적 및 암 치료제’에서 구두 발표를 할 예정입니다.
발표: “AN4035의 발견: CEACAM5를 표적으로 하는 신약 항체-약물 접합체(ADC)로, 독점적인 pan-RAS(ON) 억제제 페이로드를 탑재하고 있습니다.”
날짜 및 시간: 2025년 10월 25일 토요일, 오전 11:45–오전 12:15 ET, 3층 Ballroom AB, 하인스 컨벤션 센터. 초록이 2025년 10월 22일 게시된 후 과학적 근거와 데이터 하이라이트를 발표할 예정입니다.
Adlai Nortye (NASDAQ: ANL) participera à une présentation orale lors de la AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics à Boston, qui se tiendra du 22 au 26 octobre 2025.
Présentation : “Discovery of AN4035: un nouvel anticorps-médicament conjugué (ADC) ciblant CEACAM5, muni d’une charge utile inhibitrice pan-RAS(ON) propriétaire.”
Date et heure : samedi 25 octobre 2025, de 11 h 45 à 12 h 15 HE, Level 3 Ballroom AB, Hynes Convention Center. L’entreprise publiera le raisonnement scientifique et les points saillants des données après la publication de l’abstract le 22 octobre 2025.
Adlai Nortye (NASDAQ: ANL) wird bei der AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston einen Vortrag halten, die vom 22. bis zum 26. Oktober 2025 stattfindet.
Präsentation: „Discovery of AN4035: Ein neuartiges CEACAM5-targeting Antikörper-Wirkstoff-Konjugat (ADC), ausgestattet mit einer proprietären pan-RAS(ON) Inhibitor-Payload.“
Datum & Uhrzeit: Samstag, 25. Oktober 2025, 11:45 Uhr–12:15 Uhr ET, Level 3 Ballroom AB, Hynes Convention Center. Das Unternehmen wird die wissenschaftliche Begründung und die wichtigsten Datenpunkte nach der Veröffentlichung des Abstracts am 22. Oktober 2025 bekannt geben.
Adlai Nortye (NASDAQ: ANL) ستقدم عرضاً شفوياً في المؤتمر الدولي AACR-NCI-EORTC حول الأهداف الجزيئية وعلاجات السرطان في بوسطن، الذي سيعقد من 22 إلى 26 أكتوبر 2025.
العرض: “اكتشاف AN4035: مُقَاوِب أحادي التّلقي CEACAM5 يستهدف CEACAM5 مع حملة (payload) مثبِّط pan-RAS(ON) مملوكة.”
التاريخ والوقت: السبت 25 أكتوبر 2025، من 11:45 صباحاً إلى 12:15 ظهراً بتوقيت شرق الولايات المتحدة، القاعة Level 3 Ballroom AB، مركز هينز للمؤتمرات. ستصدر الشركة تفسيراً علمياً ونقاط بيانات رئيسية بعد نشر الملخص في 22 أكتوبر 2025.
Adlai Nortye (NASDAQ: ANL) 将在波士顿举行的 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 上进行口头报告，会议时间为 2025 年 10 月 22 日至 26 日。
报告：“AN4035 的发现：一种新型 CEACAM5 靶向的抗体药物偶联物 (ADC)，携带专有的 pan-RAS(ON) 抑制剂载荷。”
日期与时间： 2025 年 10 月 25 日，星期六，东部时间 11:45–12:15，Level 3 Ballroom AB，Hynes Convention Center。公司将在摘要于 2025 年 10 月 22 日发布后，披露科学依据及数据要点。
- None.
- None.
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it will deliver an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held from October 22-26, 2025, in Boston, MA.
Presentation details are as follows:
Abstract title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window
Date and Time: Saturday, October 25, 2025; 11:45 AM – 12:15 PM ET
Session Title: Spotlight on Proffered Papers 3: Novel Therapeutic Agents
Location: Level 3, Ballroom AB, Hynes Convention Center, Boston, MA
The Company will issue a further press release detailing the scientific rationale and data highlights for AN4035 once the abstract is made public on the AACR portal on October 22, 2025
About Adlai Nortye
Adlai Nortye (NASDAQ: ANL) is a global clinical-stage company focused on the development of innovative cancer therapies, with global R&D centers in the U.S. and China. We are advancing a portfolio of innovative drug candidates across two key therapeutic areas: next-generation PD-1/L1 modulation, including AN8025, a multifunctional fusion protein designed to modulate both T cells and antigen-presenting cells, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor; and RAS-targeted therapies, including AN9025, an oral pan-RAS(ON) inhibitor with potential to address multiple RAS-driven cancers, and AN4035, a novel CEACAM5-targeting antibody-drug conjugate armed with a potent pan-RAS(ON) inhibitor payload.
Forward-Looking Statement
This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “potential,” “continue,” “ongoing,” “targets” and similar statements. Among other things, statements that are not historical facts, including statements about the Company’s beliefs and expectations, the business outlook and quotations from management in this announcement, as well as the Company’s strategic and operational plans, are or contain forward-looking statements.
The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Factors that could cause the Company’s actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of the Company’s preclinical studies, clinical trials and other therapeutic candidate development efforts; the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether the clinical trial results will be predictive of real-world results; the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of the Company’s therapeutic candidates; the Company’s ability to establish, manage, and maintain corporate collaborations, as well as the ability of its collaborators to execute on their development and commercialization plans; the implementation of the Company’s business model and strategic plans for its business and therapeutic candidates; the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of the Company’s expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing; risks related to changes in healthcare laws, rules and regulations in the PRC and United States or elsewhere. Further information regarding these and other risks is included in the Company’s filings with the SEC. All information provided in this announcement and in the attachments is as of the date of this announcement, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
Company contact:
Investor Relations
Email: ir@adlainortye.com
FAQ
When will Adlai Nortye (ANL) present AN4035 at AACR-NCI-EORTC 2025?
What is the title of Adlai Nortye's (ANL) AACR abstract for October 2025?
Where and in which session will ANL present at the AACR-NCI-EORTC conference?
When will Adlai Nortye (ANL) release AN4035 data related to the AACR presentation?
How can investors view Adlai Nortye's (ANL) AACR presentation materials?
What therapeutic approach is AN4035 using according to the ANL presentation description?
